Liu X, Jin J, Wang B, Ge L
Front Endocrinol (Lausanne). 2024; 15:1437999.
PMID: 39583964
PMC: 11581845.
DOI: 10.3389/fendo.2024.1437999.
Liang C, Kan J, Wang J, Lu W, Mo X, Zhang B
Front Immunol. 2024; 15:1448012.
PMID: 39483474
PMC: 11524805.
DOI: 10.3389/fimmu.2024.1448012.
Sundaramurthi H, Tonelotto V, Wynne K, OConnell F, OReilly E, Costa-Garcia M
Open Res Eur. 2023; 3:88.
PMID: 37981907
PMC: 10654492.
DOI: 10.12688/openreseurope.15973.2.
Wang K, Zeng C
Adv Exp Med Biol. 2023; 1418:143-153.
PMID: 37603278
DOI: 10.1007/978-981-99-1443-2_10.
Guevara-Gutierrez E, Ramos-Suarez M, Villalobos-Ayala R, Tlacuilo-Parra A, Munoz-Valle J, Tarango-Martinez V
Mol Genet Genomic Med. 2023; 11(11):e2252.
PMID: 37485818
PMC: 10655503.
DOI: 10.1002/mgg3.2252.
MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells.
Sun H, Cheng R, Zhang D, Guo Y, Li F, Li Y
Front Oncol. 2023; 12:1028070.
PMID: 36703790
PMC: 9871987.
DOI: 10.3389/fonc.2022.1028070.
Bone Marrow Macrophages Induce Inflammation by Efferocytosis of Apoptotic Prostate Cancer Cells via HIF-1α Stabilization.
Mendoza-Reinoso V, Schnepp P, Baek D, Rubin J, Schipani E, Keller E
Cells. 2022; 11(23).
PMID: 36496973
PMC: 9737180.
DOI: 10.3390/cells11233712.
Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability.
Cao H, Tadros V, Hiramoto B, Leeper K, Hino C, Xiao J
Biomedicines. 2022; 10(5).
PMID: 35625776
PMC: 9138861.
DOI: 10.3390/biomedicines10051038.
Molecular Level Insights Into the Structural and Dynamic Factors Driving Cytokine Function.
Cui J, Lisi G
Front Mol Biosci. 2021; 8:773252.
PMID: 34760929
PMC: 8573031.
DOI: 10.3389/fmolb.2021.773252.
Extracellular vesicles in obesity and its associated inflammation.
Kumar V, Kiran S, Kumar S, Singh U
Int Rev Immunol. 2021; 41(1):30-44.
PMID: 34423733
PMC: 8770589.
DOI: 10.1080/08830185.2021.1964497.
Meningioma Tumor Microenvironment.
Sahab-Negah S, Gorji A
Adv Exp Med Biol. 2021; 1296:33-48.
PMID: 34185285
DOI: 10.1007/978-3-030-59038-3_3.
Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma.
Raieli S, Di Renzo D, Lampis S, Amadesi C, Montemurro L, Pession A
Front Oncol. 2021; 11:625207.
PMID: 33718189
PMC: 7951059.
DOI: 10.3389/fonc.2021.625207.
MIF-Dependent Control of Tumor Immunity.
Noe J, Mitchell R
Front Immunol. 2020; 11:609948.
PMID: 33324425
PMC: 7724107.
DOI: 10.3389/fimmu.2020.609948.
The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling.
Song H, Shen Q, Hu S, Jin J
Biol Open. 2020; 9(11).
PMID: 33148606
PMC: 7673366.
DOI: 10.1242/bio.053447.
Salivary alpha-1-antitrypsin and macrophage migration inhibitory factor may be potential prognostic biomarkers for oncologic treatment-induced severe oral mucositis.
Palmier N, Leme A, De Rossi T, Telles G, Morais-Faria K, Kowalski L
Support Care Cancer. 2020; 29(6):2939-2946.
PMID: 33009579
DOI: 10.1007/s00520-020-05805-2.
GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
Demir S, Timur Z, Ates N, Martinez L, Seyrantepe V
J Neuroinflammation. 2020; 17(1):277.
PMID: 32951593
PMC: 7504627.
DOI: 10.1186/s12974-020-01947-6.
Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic.
Geller A, Shrestha R, Yan J
Int J Mol Sci. 2019; 20(15).
PMID: 31344853
PMC: 6695648.
DOI: 10.3390/ijms20153618.
Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment.
Munoz-Galvan S, Lucena-Cacace A, Perez M, Otero-Albiol D, Gomez-Cambronero J, Carnero A
Oncogene. 2018; 38(8):1309-1323.
PMID: 30305726
DOI: 10.1038/s41388-018-0527-2.
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Cheon S, Kim H, Park Y, Jang J, Lim Y, Song S
Mol Oncol. 2018; 12(8):1398-1409.
PMID: 29896883
PMC: 6068346.
DOI: 10.1002/1878-0261.12345.
Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N, Lin J, Xing S, Liu D, Li S, Lai Y
Cancer Res Treat. 2018; 51(1):378-390.
PMID: 29807404
PMC: 6333976.
DOI: 10.4143/crt.2018.070.